Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
INTERVENTIONAL
Inicio: 1 de jul de 2014
ID: NCT02168946
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 25 de mar de 2022
ID: NCT04928846
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)
INTERVENTIONAL
Inicio: 1 de mar de 2007
ID: NCT00423319
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
INTERVENTIONAL
Inicio: 24 de sept de 2018
ID: NCT03573505
Terminado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
INTERVENTIONAL
Inicio: 31 de may de 2016
ID: NCT02745145
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 27 de feb de 2025
ID: NCT06780137
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Who Are at High Risk for RSV-related Disease Progression
INTERVENTIONAL
Inicio: 17 de nov de 2021
ID: NCT04978337
Completado
Fase 3
ClinicalTrials.gov
A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
INTERVENTIONAL
Inicio: 1 de dic de 2011
ID: NCT01444430
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
INTERVENTIONAL
Inicio: 10 de abr de 2025
ID: NCT06868277
Terminado
Fase 2
ClinicalTrials.gov
A 52-week, Randomised, Double Blind, Multicentre, 2-arm Parallel Group Trial Assessing Efficacy of CHF6001 (Total Daily Dose 3200μg) Dry Powder Inhaler (DPI) add-on to Maintenance Medium or High Dose of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists in Subjects With Uncontrolled Asthma
INTERVENTIONAL
Inicio: 26 de nov de 2023
ID: NCT06029595
Completado
Fase 3
ClinicalTrials.gov
HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 25 de sept de 2009
ID: NCT01017952
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
INTERVENTIONAL
Inicio: 19 de ago de 2021
ID: NCT04849728
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a
INTERVENTIONAL
Inicio: 31 de may de 2024
ID: NCT06261957
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
INTERVENTIONAL
Inicio: 6 de sept de 2021
ID: NCT04583280
Terminado
Fase 3
ClinicalTrials.gov
Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.
INTERVENTIONAL
Inicio: 1 de dic de 2005
ID: NCT00269828
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
INTERVENTIONAL
Inicio: 1 de dic de 2010
ID: NCT01168973
Desconocido
ClinicalTrials.gov
BUSQUEDA ACTIVA DE CASOS DE EPOC EN EL PRIMER NIVEL DE ATENCION: USO DEL SCORE PUMA PARA TAMIZAJE DE EPOC
OBSERVATIONAL
Inicio: 14 de nov de 2018
ID: NCT03713931
Retirado
Fase 3
ClinicalTrials.gov
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
INTERVENTIONAL
Inicio: 1 de dic de 2013
ID: NCT01860066
Activo, no recluta
Fase 3
ClinicalTrials.gov
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
INTERVENTIONAL
Inicio: 3 de oct de 2014
ID: NCT02152631
Terminado
Fase 3
ClinicalTrials.gov
Inhaled Pre-prandial Human Insulin Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Chronic Obstructive Pulmonary Disease: A 52-week Open Label, Multicentre, Randomized, Parallel Trial to Investigate Long-term Safety
INTERVENTIONAL
Inicio: 15 de may de 2007
ID: NCT00472953
Anterior
1
...
31
32
33
...
434
Siguiente
Filtros